88 results on '"Celli, N."'
Search Results
2. WINTERC-G: mapping the upper mantle thermochemical heterogeneity from coupled geophysical–petrological inversion of seismic waveforms, heat flow, surface elevation and gravity satellite data
- Author
-
Fullea, J, primary, Lebedev, S, additional, Martinec, Z, additional, and Celli, N L, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
- Author
-
Caraceni, P, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Boccia, S, Svegliati-Baroni, G, Fagiuoli, S, Romanelli, R, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Tortora, A, De Marco, R, Angelico, M, Cacciola, I, Elia, G, Federico, A, Massironi, S, Guarisco, R, Galioto, A, Ballardini, G, Rendina, M, Nardelli, S, Piano, S, Elia, C, Prestianni, L, Cappa, F, Cesarini, L, Simone, L, Pasquale, C, Cavallin, M, Andrealli, A, Fidone, F, Ruggeri, M, Roncadori, A, Baldassarre, M, Tufoni, M, Zaccherini, G, Bernardi, M, Domenicali, M, Giannone, F, Merli, M, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Maiorca, D, Rizzotto, A, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Alberti, A, Mazzarelli, C, Vangeli, M, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Laffi, G, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Gasbarrini, A, Leo, P, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Negri, E, Dallio, M, Loguercio, C, Conte, D, Celli, N, Bringiotti, R, Castellaneta, N, Salerno, F, Caraceni P., Riggio O., Angeli P., Alessandria C., Neri S., Foschi F. G., Levantesi F., Airoldi A., Boccia S., Svegliati-Baroni G., Fagiuoli S., Romanelli R. G., Cozzolongo R., Di Marco V., Sangiovanni V., Morisco F., Toniutto P., Tortora A., De Marco R., Angelico M., Cacciola I., Elia G., Federico A., Massironi S., Guarisco R., Galioto A., Ballardini G., Rendina M., Nardelli S., Piano S., Elia C., Prestianni L., Cappa F. M., Cesarini L., Simone L., Pasquale C., Cavallin M., Andrealli A., Fidone F., Ruggeri M., Roncadori A., Baldassarre M., Tufoni M., Zaccherini G., Bernardi M., Domenicali M., Giannone F. A., Merli M., Gioia S., Fasolato S., Sticca A., Campion D., Risso A., Saracco G. M., Maiorca D., Rizzotto A., Lanzi A., Neri E., Visani A., Mastroianni A., Alberti A. B., Mazzarelli C., Vangeli M., Marzioni M., Capretti F., Kostandini A., Magini G., Colpani M., Laffi G., Gabbani T., Marsico M., Zappimbulso M., Petruzzi J., Calvaruso V., Parrella G., Caporaso N., Auriemma F., Guarino M., Pugliese F., Gasbarrini A., Leo P., De Leonardis F., Pecchioli A., Rossi P., Raimondo G., Negri E., Dallio M., Loguercio C., Conte D., Celli N., Bringiotti R., Castellaneta N. M., Salerno F., Caraceni, P, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Boccia, S, Svegliati-Baroni, G, Fagiuoli, S, Romanelli, R, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Tortora, A, De Marco, R, Angelico, M, Cacciola, I, Elia, G, Federico, A, Massironi, S, Guarisco, R, Galioto, A, Ballardini, G, Rendina, M, Nardelli, S, Piano, S, Elia, C, Prestianni, L, Cappa, F, Cesarini, L, Simone, L, Pasquale, C, Cavallin, M, Andrealli, A, Fidone, F, Ruggeri, M, Roncadori, A, Baldassarre, M, Tufoni, M, Zaccherini, G, Bernardi, M, Domenicali, M, Giannone, F, Merli, M, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Maiorca, D, Rizzotto, A, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Alberti, A, Mazzarelli, C, Vangeli, M, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Laffi, G, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Gasbarrini, A, Leo, P, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Negri, E, Dallio, M, Loguercio, C, Conte, D, Celli, N, Bringiotti, R, Castellaneta, N, Salerno, F, Caraceni P., Riggio O., Angeli P., Alessandria C., Neri S., Foschi F. G., Levantesi F., Airoldi A., Boccia S., Svegliati-Baroni G., Fagiuoli S., Romanelli R. G., Cozzolongo R., Di Marco V., Sangiovanni V., Morisco F., Toniutto P., Tortora A., De Marco R., Angelico M., Cacciola I., Elia G., Federico A., Massironi S., Guarisco R., Galioto A., Ballardini G., Rendina M., Nardelli S., Piano S., Elia C., Prestianni L., Cappa F. M., Cesarini L., Simone L., Pasquale C., Cavallin M., Andrealli A., Fidone F., Ruggeri M., Roncadori A., Baldassarre M., Tufoni M., Zaccherini G., Bernardi M., Domenicali M., Giannone F. A., Merli M., Gioia S., Fasolato S., Sticca A., Campion D., Risso A., Saracco G. M., Maiorca D., Rizzotto A., Lanzi A., Neri E., Visani A., Mastroianni A., Alberti A. B., Mazzarelli C., Vangeli M., Marzioni M., Capretti F., Kostandini A., Magini G., Colpani M., Laffi G., Gabbani T., Marsico M., Zappimbulso M., Petruzzi J., Calvaruso V., Parrella G., Caporaso N., Auriemma F., Guarino M., Pugliese F., Gasbarrini A., Leo P., De Leonardis F., Pecchioli A., Rossi P., Raimondo G., Negri E., Dallio M., Loguercio C., Conte D., Celli N., Bringiotti R., Castellaneta N. M., and Salerno F.
- Abstract
Background: Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods: We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings: From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation: In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding: Italian Medicine Agency.
- Published
- 2018
4. The upper mantle beneath the South Atlantic Ocean, South America and Africa from waveform tomography with massive data sets
- Author
-
Celli, N. L., Lebedev, S., Schaeffer, A. J., Ravenna, M., Gaina, C., Celli, N. L., Lebedev, S., Schaeffer, A. J., Ravenna, M., and Gaina, C.
- Abstract
We present a tomographic model of the crust, upper mantle and transition zone beneath the South Atlantic, South America and Africa. Taking advantage of the recent growth in broadband data sampling, we compute the model using waveform fits of over 1.2 million vertical-component seismograms, obtained with the automated multimode inversion of surface, S and multiple S waves. Each waveform provides a set of linear equations constraining perturbations with respect to a 3-D reference model within an approximate sensitivity volume. We then combine all equations into a large linear system and solve it for a 3-D model of Sand P-wave speeds and azimuthal anisotropy within the crust, upper mantle and uppermost lower mantle. In South America and Africa, our new model SA2019 reveals detailed structure of the lithosphere, with structure of the cratons within the continents much more complex than seen previously. In South America, lower seismic velocities underneath the transbrasilian lineament (TBL) separate the high-velocity anomalies beneath the Amazon Craton from those beneath the São Francisco and Paraná Cratons. We image the buried portions of the Amazon Craton, the thick cratonic lithosphere of the Paraná and Parnaiba Basins and an apparently cratonic block wedged between western Guyana and the slab to the west of it, unexposed at the surface. Thick cratonic lithosphere is absent under the Archean crust of the São Luis, Luis Álves and Rio de La Plata Cratons, next to the continental margin. The Guyana Highlands are underlain by low velocities, indicating hot asthenosphere. In the transition zone, we map the subduction of the Nazca Plate and the Chile Rise under Patagonia. Cratonic lithosphere beneath Africa is more fragmented than seen previously, with separate cratonic units observed within the West African and Congo Cratons, and with cratonic lithosphere absent beneath large portions of Archean crust. We image the lateral extent of the Niassa Craton, hypothesized previ
- Published
- 2020
5. The upper mantle beneath the South Atlantic Ocean, South America and Africa from waveform tomography with massive data sets
- Author
-
Celli, N L, primary, Lebedev, S, additional, Schaeffer, A J, additional, Ravenna, M, additional, and Gaina, C, additional
- Published
- 2020
- Full Text
- View/download PDF
6. CAPE (Caffeic Acid Phenethyl Ester)-based Propolis Extract (Bio 30) Suppresses the Growth of Human Neuro.bromatosis (NF) Tumor Xenografts in Mice
- Author
-
Demestre, M., Messerli, S. M., Celli, N., Shahhossini, M., Kluwe, L., Mautner, V., and Maruta, H.
- Published
- 2009
- Full Text
- View/download PDF
7. Erosion of cratons by plumes: A seismological perspective
- Author
-
Lebedev, S., Celli, N., Schaeffer , A., Steinberger, B., and Meier, T.
- Abstract
How cratons, the ancient cores of continents, evolved since their formation over 2.5 Ga ago is debated. Seismictomography can map the thick lithosphere of cratons and, with its resolution now reaching regional scales in mostcontinents, it reveals a more complex, fragmented cratonic lithosphere than seen previously. Joint analysis ofthe information on the present state of the lithosphere from tomography and its past state from diamondiferouskimberlites reveals surprisingly common lithospheric erosion over the last few hundred million years. Largeigneous provinces or hotspot tracks, attributed to deep-mantle plumes, tend to occur near the lithosphere-losslocations. This suggests that the cratonic roots foundered once modified by mantle plumes. Our results imply thatthe total volume of cratonic lithosphere has decreased substantially since its Archean formation, with the fate ofeach craton depending on its plate-tectonic movements relative to mantle plumes.
- Published
- 2019
8. Review article: percutaneous treatment of hepatocellular carcinoma
- Author
-
GAIANI, S., CELLI, N., CECILIONI, L., PISCAGLIA, F., and BOLONDI, L.
- Published
- 2003
9. The DPEP Long-Period Detector for the NOA Broadband Array
- Author
-
Celli, N. L., Schweitzer, J., and Fyen, J.
- Published
- 2015
- Full Text
- View/download PDF
10. Characterization of Small Nodules (1-3 cm) in Cirrhosis. The role of Perfusional Angiosonography, Spiral Computed Tomography and Double Contrast Magnetic Resonance
- Author
-
Leoni S, Piscaglia F, Celli N, CAMAGGI, VALERIA, Silvagni E, Fusco F, Bazzocchi A, Golfieri R, Bolondi L, and Leoni S, Piscaglia F, Celli N, Camaggi V, Silvagni E, Fusco F, Bazzocchi A, Golfieri R, Bolondi L
- Subjects
Cirrhosi ,Small Nodule ,Double Contrast Magnetic Resonance ,Spiral Computed Tomography ,Perfusional Angiosonography - Published
- 2006
11. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations
- Author
-
Piscaglia, F, Bolondi, L, Italian Society for Ultrasound in Medicine, Aiani, Biology Study Group on Ultrasound Contrast Agents 1 L., Luigi Angeli, M., Arienti, V., Barozzi, L., Basilico, R., Bertolotto, M., Biasini, E., Busilacchi, P., Calliada, F., Caremani, * M., Caturelli, E., Celli, N., Colecchia, A., Cova, L., Assunta Cova, M., Crocetti, L., de Sio, I., Drudi, Francesco Maria, Ferraioli, G., Filice, C., Fornari, F., Gaiani, S., Giangregorio, F., Giorgio, A., Ierace, T., Lencioni, R., Livraghi, T., Magnolfi, F., Martegani, A., Meloni, F., Menozzi, G., Pelosi, G., Pompili, M., Riccardi, L., Ricci, P., Rubaltelli, L., Sacerdoti, D., Serafini, G., Serra, C., Solbiati, L., Tacconi, D., Valentino, M., Vidili, G., Vitali, F., Piscaglia F., Bolondi L., and Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents.
- Subjects
medicine.medical_specialty ,Acoustics and Ultrasonics ,Sulfur Hexafluoride ,Biophysics ,Contrast Media ,Abdomen ,medicine ,Retrospective analysis ,Adverse Drug Reaction Reporting Systems ,Humans ,Radiology, Nuclear Medicine and imaging ,Adverse effect ,Phospholipids ,Retrospective Studies ,Ultrasonography ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Magnetic resonance imaging ,Retrospective cohort study ,Safety profile ,medicine.anatomical_structure ,Liver ,Abdominal examination ,Radiology ,business - Abstract
The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents.
- Published
- 2006
12. Effect of Aplidin in acute lymphoblastic leukaemia cells
- Author
-
Erba, E, Serafini, M, Gaipa, G, Tognon, G, Marchini, S, Celli, N, Rotilio, D, Broggini, M, Jimeno, J, Faircloth, G, Biondi, A, D'Incalci, M, Faircloth, G T, Erba, E, Serafini, M, Gaipa, G, Tognon, G, Marchini, S, Celli, N, Rotilio, D, Broggini, M, Jimeno, J, Faircloth, G, Biondi, A, D'Incalci, M, and Faircloth, G T
- Abstract
The cytotoxic effect of Aplidin was investigated on fresh leukaemia cells derived from children with B-cell-precursor (BCP) acute lymphoblastic leukaemia (ALL) by using stromal-layer culture system and on four cell lines, ALL-PO, Reh, ALL/MIK and TOM-1, derived from patients with ALL with different molecular genetic abnormalities. In ALL cell lines Aplidin was cytotoxic at nanomolar concentrations. In the ALL cell lines the drug-induced cell death was clearly related to the induction of apoptosis and appeared to be p53-independent. Only in ALL-PO 20 nM Aplidin treatment caused a block of vascular endothelial growth factor (VEGF) secretion and downregulation of VEGF-mRNA, but Aplidin cytotoxicity does not seem to be related to VEGF inhibition since the sensitivity of ALL-PO cells to Aplidin is comparable to that observed for the other cells used. Aplidin induced a G1 and a G2 M block in ALL cell lines. In patient-derived leukaemia cells, Aplidin induced a strong cytotoxicity evidenced in a stroma-supported immunocytometric assay. Cells from children with genetic abnormalities such as t(9;22) and t(4;11) translocations, associated with an inferior treatment outcome, were sensitive to Aplidin to the same extent as that observed in other BCP-ALL cases. Aplidin exerted a strong cell killing effect (>88%) against primary culture cells from five relapsed ALL cases, at concentrations much lower than those reported to be achieved in plasma of patients receiving Aplidin at recommended doses. Taken together these data suggest that Aplidin could be a new anticancer drug to be investigated in ALL patients resistant to available therapy.
- Published
- 2003
13. CAPE (caffeic acid phenethyl ester)‐based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice
- Author
-
Demestre, M., primary, Messerli, S. M., additional, Celli, N., additional, Shahhossini, M., additional, Kluwe, L., additional, Mautner, V., additional, and Maruta, H., additional
- Published
- 2008
- Full Text
- View/download PDF
14. Percutaneous radio-frequency ablation of small HCC: Factors related to clinical outcome and recurrence of disease
- Author
-
Piscaglia, F., primary, Celli, N., additional, Zocco, M.A., additional, Mancini, M., additional, Sagrini, E., additional, Gianstefani, A., additional, Bazzocchi, A., additional, Costantini, S., additional, Righini, R., additional, and Bolondi, L., additional
- Published
- 2008
- Full Text
- View/download PDF
15. Development and validation of a liquid chromatographic–tandem mass spectrometric method for the determination of caffeic acid phenethyl ester in rat plasma and urine
- Author
-
CELLI, N, primary, MARIANI, B, additional, DRAGANI, L, additional, MURZILLI, S, additional, ROSSI, C, additional, and ROTILIO, D, additional
- Published
- 2004
- Full Text
- View/download PDF
16. Effect of Aplidin in acute lymphoblastic leukaemia cells
- Author
-
Erba, E, primary, Serafini, M, additional, Gaipa, G, additional, Tognon, G, additional, Marchini, S, additional, Celli, N, additional, Rotilio, D, additional, Broggini, M, additional, Jimeno, J, additional, Faircloth, G T, additional, Biondi, A, additional, and D'Incalci, M, additional
- Published
- 2003
- Full Text
- View/download PDF
17. Percutaneous treatment of hepatocellular carcinoma
- Author
-
Gaiani, S., primary, Celli, N., additional, Cecilioni, L., additional, Piscaglia, F., additional, and Bolondi, L., additional
- Published
- 2003
- Full Text
- View/download PDF
18. Perfusional angiosonography with a second generation ultrasound contrast agent in the characterization of small nodules in cirrhosis
- Author
-
Gaiani, S., primary, Celli, N., additional, Piscaglia, F., additional, Cecilioni, L., additional, Mancini, M., additional, Crespi, C., additional, Rasciti, L., additional, and Bolondi, L., additional
- Published
- 2003
- Full Text
- View/download PDF
19. Pattern of enhancement timing in focal nodular hyperplasia (FNH) investigated by perfusional angiosonography
- Author
-
Gaiani, S., primary, Piscaglia, F., additional, Masi, L., additional, Celli, N., additional, Cecilioni, L., additional, Giangregorio, F., additional, Fornari, F., additional, and Bolondi, L., additional
- Published
- 2003
- Full Text
- View/download PDF
20. Hepatocellular carcinoma treated with radiofrequency ablation: evaluation of posttreatment response with a new contrast-enhanced harmonic sonography
- Author
-
Giangregorio, F., primary, Marinone, M.G., additional, Di Stasi, M., additional, Celli, N., additional, Gaiani, S., additional, Bolondi, L., additional, and Fornari, F., additional
- Published
- 2003
- Full Text
- View/download PDF
21. Perfusional angiosonography in the detection of hypervasculariy in small (<3cm) HCC in cirrhosis
- Author
-
Gaiani, S., primary, Celli, N., additional, Cecilioni, L., additional, Piscaglia, F., additional, Giangregorio, F., additional, Losinno, F., additional, Fornari, F., additional, and Bolondi, L., additional
- Published
- 2003
- Full Text
- View/download PDF
22. Liquid chromatography–tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration
- Author
-
DELBOCCIO, P, primary, DIDEO, A, additional, DECURTIS, A, additional, CELLI, N, additional, IACOVIELLO, L, additional, and ROTILIO, D, additional
- Published
- 2003
- Full Text
- View/download PDF
23. 2 PS Collagenase-3 expression in liver tumors
- Author
-
Celli, N., primary, Knittel, T., additional, Mehde, M., additional, Bacchini, P., additional, Pini, P., additional, Bolondi, L., additional, and Piscaglia, F., additional
- Published
- 2002
- Full Text
- View/download PDF
24. 17 OC Recurrence after percutaneous radio-frequency thermal ablation in previously treated and untreated hepatocellular carcinoma
- Author
-
Gaiani, S., primary, Celli, N., additional, Piscaglia, F., additional, Giangregorio, F., additional, Cecilioni, L., additional, Crespi, C., additional, Fornari, F., additional, and Bolondi, L., additional
- Published
- 2002
- Full Text
- View/download PDF
25. Influence of the Spleen on Portal Haemodynamics: a Non-invasive Study with Doppler Ultrasound in Chronic Liver Disease and Haematological Disorders
- Author
-
Piscaglia, F., primary, Donati, G., additional, Cecilioni, L., additional, Celli, N., additional, Stagni, B., additional, Pini, P., additional, Gaiani, S., additional, Gherlinzoni, F., additional, and Bolondi, L., additional
- Published
- 2002
- Full Text
- View/download PDF
26. Influence of Liver Fibrosis on Hepatic Artery Doppler Resistance Index in Chronic Hepatitis of Viral Origin
- Author
-
Piscaglia, F., primary, Gaiani, S., additional, Calderoni, D., additional, Donati, G., additional, Celli, N., additional, Gramantieri, L., additional, Crespi, C., additional, and Bolondi, L., additional
- Published
- 2001
- Full Text
- View/download PDF
27. Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound
- Author
-
Raymond, E., primary, Paz-Ares, L., additional, Izquierdo, M., additional, Belanger, K., additional, Maroun, J., additional, Bowman, A., additional, Anthoney, A., additional, Jodrell, D., additional, Armand, J.P., additional, Cortes-Funes, H., additional, Germa-Lluch, J., additional, Twelves, C., additional, Celli, N., additional, Guzman, C., additional, and Jimeno, J., additional
- Published
- 2001
- Full Text
- View/download PDF
28. Characterization of liver lesions by real-time contrast-enhanced ultrasonography.
- Author
-
Celli N, Gaiani S, Piscaglia F, Zironi G, Camaggi V, Leoni S, Righini R, Bolondi L, Celli, Natascia, Gaiani, Stefano, Piscaglia, Fabio, Zironi, Gianni, Camaggi, Valeria, Leoni, Simona, Righini, Roberto, and Bolondi, Luigi
- Published
- 2007
- Full Text
- View/download PDF
29. Ruthenium sulfophthalocyanine catalyst for the oxidation of chlorinated olefins with hydrogen peroxide
- Author
-
Bressan, M., Celli, N., d'Alessandro, N., Liberatore, L., Morvillo, A., and Tonucci, L.
- Published
- 2000
- Full Text
- View/download PDF
30. Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry
- Author
-
Celli, N., Gallardo, A.M., Rossi, C., Zucchetti, M., D'Incalci, M., and Rotilio, D.
- Published
- 1999
- Full Text
- View/download PDF
31. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
- Author
-
Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, ANSWER Study Investigators, Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, Caraceni P1, Riggio O2, Angeli P3, Alessandria C4, Neri S5, Foschi FG6, Levantesi F7, Airoldi A8, Boccia S9, Svegliati-Baroni G10, Fagiuoli S11, Romanelli RG12, Cozzolongo R13, Di Marco Vito, Sangiovanni V15, Morisco F16, Toniutto P17, Tortora A18, De Marco R19, Angelico M20, Cacciola I21, Elia G22, Federico A23, Massironi S24, Guarisco R25, Galioto A26, Ballardini G27, Rendina M28, Nardelli S2, Piano S3, Elia C4, Prestianni L5, Cappa FM6, Cesarini L8, Simone L9, Pasquale C2, Cavallin M3, Andrealli A4, Fidone F5, Ruggeri M29, Roncadori A30, Baldassarre M1, Tufoni M1, Zaccherini G1, Bernardi M31, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso Vincenza, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso V, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni, P, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Boccia, S, Svegliati-Baroni, G, Fagiuoli, S, Romanelli, R, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Tortora, A, De Marco, R, Angelico, M, Cacciola, I, Elia, G, Federico, A, Massironi, S, Guarisco, R, Galioto, A, Ballardini, G, Rendina, M, Nardelli, S, Piano, S, Elia, C, Prestianni, L, Cappa, F, Cesarini, L, Simone, L, Pasquale, C, Cavallin, M, Andrealli, A, Fidone, F, Ruggeri, M, Roncadori, A, Baldassarre, M, Tufoni, M, Zaccherini, G, Bernardi, M, Domenicali, M, Giannone, F, Merli, M, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Maiorca, D, Rizzotto, A, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Alberti, A, Mazzarelli, C, Vangeli, M, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Laffi, G, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Gasbarrini, A, Leo, P, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Negri, E, Dallio, M, Loguercio, C, Conte, D, Celli, N, Bringiotti, R, Castellaneta, N, and Salerno, F
- Subjects
Liver Cirrhosis ,Male ,Time Factors ,Cirrhosis ,Kaplan-Meier Estimate ,law.invention ,ascites ,0302 clinical medicine ,Hepatorenal syndrome ,Randomized controlled trial ,Furosemide ,law ,Ascites ,Clinical endpoint ,Paracentesis ,Diuretics ,albumin, decompensated cirrhosi ,Mineralocorticoid Receptor Antagonists ,Settore MED/12 - Gastroenterologia ,Medicine (all) ,Hazard ratio ,General Medicine ,Middle Aged ,Survival Rate ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Quality-Adjusted Life Years ,medicine.symptom ,Hyponatremia ,medicine.medical_specialty ,03 medical and health sciences ,Albumins ,Internal medicine ,medicine ,Humans ,Survival rate ,albumin ,Aged ,business.industry ,cirrhosis ,medicine.disease ,Clinical trial ,albumin, cirrhosis, ascites, liver decompensation ,Quality of Life ,Hyperkalemia ,business ,Esophagus Varices, Portal Hypertension, Varicosis - Abstract
Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding Italian Medicine Agency. Copyright © 2018 Elsevier Ltd. All rights reserved.
- Published
- 2018
32. Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma
- Author
-
Simona Leoni, Luigi Bolondi, N. Celli, Rita Golfieri, Anna Maria Venturi, W. F. Grigioni, Stefano Gaiani, Fabio Piscaglia, Bolondi L., Gaiani S., Celli N., Golfieri R., Grigioni W.F., Leoni S., Venturi A., and Piscaglia F.
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Vascularity ,Biopsy ,Carcinoma ,Humans ,Medicine ,Body Weights and Measures ,Prospective Studies ,Aged ,Neoplasm Staging ,Ultrasonography ,Hepatology ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Nodule (medicine) ,Hypervascularity ,Middle Aged ,medicine.disease ,Liver ,Dysplasia ,Hepatocellular carcinoma ,Female ,Radiology ,medicine.symptom ,business ,Tomography, Spiral Computed - Abstract
In a prospective study, we examined the impact of arterial hypervascularity, as established by the European Association for the Study of the Liver (EASL) recommendations, as a criterion for characterizing small (1-3 cm) nodules in cirrhosis. A total of 72 nodules (1-2 cm, n = 41; 2.1-3 cm, n = 31) detected by ultrasonography in 59 patients with cirrhosis were included in the study. When coincidental arterial hypervascularity was detected at contrast perfusional ultrasonography and helical computed tomography, the lesion was considered to be hepatocellular carcinoma (HCC) according to EASL criteria. When one or both techniques showed negative results, ultrasound-guided biopsy was performed. In cases with negative results for malignancy or high-grade dysplasia, biopsy was repeated when an increase in size was detected at the 3-month follow-up examination. Coincidental hypervascularity was found in 44 of 72 nodules (61%; 44% of 1-2-cm nodules and 84% of 2-3-cm nodules). Fourteen nodules (19.4%) had negative results with both techniques (hypovascular nodules). Biopsy showed HCC in 5 hypovascular nodules and in 11 of 14 nodules with hypervascularity using only one technique. All nodules larger than 2 cm finally resulted to be HCC. Not satisfying the EASL imaging criteria for diagnosis were 38% of HCCs 1 to 2 cm (17% hypovascular) and 16% of those 2 to 3 cm (none hypovascular). In conclusion, the noninvasive EASL criteria for diagnosis of HCC are satisfied in only 61% of small nodules in cirrhosis; thus, biopsy frequently is required in this setting. Relying on imaging techniques in nodules of 1 to 2 cm would miss the diagnosis of HCC in up to 38% of cases. Any nodule larger than 2 cm should be regarded as highly suspicious for HCC.
- Published
- 2005
33. Characterization of liver lesions by real-time contrast-enhanced ultrasonology
- Author
-
CELLI, NATASCIA, GAIANI, STEFANO, PISCAGLIA, FABIO, LEONI, SIMONA, RIGHINI, ROBERTO, BOLONDI, LUIGI, Zironi G., Camaggi V., Celli N., Gaiani S., Piscaglia F., Zironi G., Camaggi V., Leoni S., Righini R., and Bolondi L.
- Published
- 2007
34. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography
- Author
-
N. Celli, Fabio Fornari, Stefano Gaiani, Mikaela Mancini, L. Cecilioni, P. Pini, Franco Losinno, F. Giangregorio, Luigi Bolondi, Fabio Piscaglia, Gaiani S., Celli N., Piscaglia F., Cecilioni L., Losinno F., Giangregorio F., Mancini M., Pini P., Fornari F., and Bolondi L.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Contrast Media ,Magnetic resonance angiography ,medicine ,Humans ,Prospective Studies ,Ultrasonography, Doppler, Color ,Spiral ,Aged ,Hepatology ,medicine.diagnostic_test ,business.industry ,Ultrasound ,Liver Neoplasms ,Hypervascularity ,Middle Aged ,medicine.disease ,Spiral computed tomography ,Hepatocellular carcinoma ,Female ,Tomography ,Radiology ,business ,Nuclear medicine ,Tomography, Spiral Computed ,Mechanical index ,Magnetic Resonance Angiography - Abstract
Background/Aims Diagnosis of hepatocellular carcinoma (HCC) relies strongly on the detection of hypervascularity in the arterial phase and, in this setting, spiral computed tomography (CT) is the most widely used method. This prospective study aimed to investigate the usefulness of low mechanical index harmonic ultrasound (US), using a second generation contrast-enhanced technique, in the assessment of vascular pattern of HCC shown to be hypervascular at spiral CT. Methods A total of 79 cirrhotic patients with 103 nodules (mean±SD 28±13 mm) with arterial hypervascularity at spiral CT were studied. US examination was performed by perfusional sonography, using a new dedicated technology (CnTI-Esaote™), operating at low mechanical index, after injection of a second generation contrast agent (SonoVue™-Bracco), allowing detection of tumoral flow during arterial phase. Results Selective arterial enhancement on perfusional sonography was observed in 94 /103 nodules (91.3%), with a sensitivity of 66.6, 87.5, 91.7, and 97.3% in nodules ≤1 cm, >1≤2 cm, >2≤3 cm, and >3 cm respectively. Conclusions Perfusional sonography shows good diagnostic agreement with spiral CT in hypervascular HCC and may be proposed for the immediate vascular characterization of nodules detected at US and used as second imaging technique to confirm hypervascularity in cirrhotic nodules.
- Published
- 2003
35. Effect of Aplidin in acute lymphoblastic leukaemia cells
- Author
-
Gianluca Tognon, Massimo Broggini, Andrea Biondi, Giuseppe Gaipa, Marta Serafini, Glynn Faircloth, Domenico Rotilio, Nicola Celli, Sergio Marchini, Jose Jimeno, Eugenio Erba, Maurizio D'Incalci, Erba, E, Serafini, M, Gaipa, G, Tognon, G, Marchini, S, Celli, N, Rotilio, D, Broggini, M, Jimeno, J, Faircloth, G, Biondi, A, and D'Incalci, M
- Subjects
Male ,Vascular Endothelial Growth Factor A ,Cancer Research ,Adolescent ,Antineoplastic Agents ,Apoptosis ,Endothelial Growth Factors ,Biology ,Cell cycle ,Peptides, Cyclic ,Mass Spectrometry ,Depsipeptides ,Acute lymphocytic leukemia ,Tumor Cells, Cultured ,medicine ,Marine natural compound ,Humans ,Cytotoxic T cell ,Experimental Therapeutics ,RNA, Messenger ,RNA, Neoplasm ,Child ,Cytotoxicity ,B-Lymphocytes ,Lymphokines ,Stroma-supported immunocytometric assay ,Dose-Response Relationship, Drug ,Caspase 3 ,Vascular Endothelial Growth Factors ,Lymphokine ,Apoptosi ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,marine natural compounds ,Cell killing ,Oncology ,Drug Resistance, Neoplasm ,Cell culture ,Caspases ,Child, Preschool ,Karyotyping ,Immunology ,Cancer research ,Intercellular Signaling Peptides and Proteins ,Female ,Stromal Cells - Abstract
The cytotoxic effect of Aplidin was investigated on fresh leukaemia cells derived from children with B-cell-precursor (BCP) acute lymphoblastic leukaemia (ALL) by using stromal-layer culture system and on four cell lines, ALL-PO, Reh, ALL/MIK and TOM-1, derived from patients with ALL with different molecular genetic abnormalities. In ALL cell lines Aplidin was cytotoxic at nanomolar concentrations. In the ALL cell lines the drug-induced cell death was clearly related to the induction of apoptosis and appeared to be p53-independent. Only in ALL-PO 20 nM Aplidin treatment caused a block of vascular endothelial growth factor (VEGF) secretion and downregulation of VEGF-mRNA, but Aplidin cytotoxicity does not seem to be related to VEGF inhibition since the sensitivity of ALL-PO cells to Aplidin is comparable to that observed for the other cells used. Aplidin induced a G(1) and a G(2) M block in ALL cell lines. In patient-derived leukaemia cells, Aplidin induced a strong cytotoxicity evidenced in a stroma-supported immunocytometric assay. Cells from children with genetic abnormalities such as t(9;22) and t(4;11) translocations, associated with an inferior treatment outcome, were sensitive to Aplidin to the same extent as that observed in other BCP-ALL cases. Aplidin exerted a strong cell killing effect (88%) against primary culture cells from five relapsed ALL cases, at concentrations much lower than those reported to be achieved in plasma of patients receiving Aplidin at recommended doses. Taken together these data suggest that Aplidin could be a new anticancer drug to be investigated in ALL patients resistant to available therapy.
- Published
- 2003
36. Water-soluble platinum phthalocyanines as potential antitumor agents.
- Author
-
Bologna G, Lanuti P, D'Ambrosio P, Tonucci L, Pierdomenico L, D'Emilio C, Celli N, Marchisio M, d'Alessandro N, Santavenere E, Bressan M, and Miscia S
- Subjects
- Antineoplastic Agents chemistry, Antineoplastic Agents metabolism, Cell Cycle drug effects, Cell Movement drug effects, Cell Proliferation drug effects, Drug Screening Assays, Antitumor, Female, Humans, Indoles chemistry, Indoles metabolism, MCF-7 Cells, Organoplatinum Compounds chemistry, Organoplatinum Compounds metabolism, Solubility, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Indoles pharmacology, Organoplatinum Compounds pharmacology, Water chemistry
- Abstract
Breast cancer represents the second cause of death in the European female population. The lack of specific therapies together with its high invasive potential are the major problems associated to such a tumor. In the last three decades platinum-based drugs have been considered essential constituents of many therapeutic strategies, even though with side effects and frequent generation of drug resistance. These drugs have been the guide for the research, in last years, of novel platinum and ruthenium based compounds, able to overcome these limitations. In this work, ruthenium and platinum based phthalocyanines were synthesized through conventional techniques and their antiproliferative and/or cytotoxic actions were tested. Normal mammary gland (MCF10A) and several models of mammarian carcinoma at different degrees of invasiveness (BT474, MCF-7 and MDA-MB-231) were used. Cells were treated with different concentrations (5-100 μM) of the above reported compounds, to evaluate toxic concentration and to underline possible dose-response effects. The study included growth curves made by trypan blue exclusion test and scratch assay to study cellular motility and its possible negative modulation by phthalocyanine. Moreover, we investigated cell cycle and apoptosis through flow cytometry and AMNIS Image Stream cytometer. Among all the tested drugs, tetrasulfonated phthalocyanine of platinum resulted to be the molecule with the best cytostatic action on neoplastic cell lines at the concentration of 30 μM. Interestingly, platinum tetrasulfophtalocyanine, at low doses, had no antiproliferative effects on normal cells. Therefore, such platinum complex, appears to be a promising drug for mammarian carcinoma treatment.
- Published
- 2014
- Full Text
- View/download PDF
37. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
- Author
-
Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, and Moschetta A
- Subjects
- Animals, Cholestasis metabolism, Cholestasis pathology, Cholesterol 7-alpha-Hydroxylase metabolism, Fibroblast Growth Factors metabolism, Liver pathology, Male, Mice, Mice, Transgenic, Random Allocation, Receptors, Cytoplasmic and Nuclear genetics, Bile Acids and Salts metabolism, Cholestasis prevention & control, Intestinal Mucosa metabolism, Liver metabolism, Receptors, Cytoplasmic and Nuclear metabolism, Transcriptional Activation
- Abstract
Background & Aims: Cholestasis is a liver disorder characterized by impaired bile flow, reduction of bile acids (BAs) in the intestine, and retention of BAs in the liver. The farnesoid X receptor (FXR) is the transcriptional regulator of BA homeostasis. Activation of FXR by BAs reduces circulating BA levels in a feedback mechanism, repressing hepatic cholesterol 7α-hydroxylase (Cyp7a1), the rate-limiting enzyme for the conversion of cholesterol to BAs. This mechanism involves the hepatic nuclear receptor small heterodimer partner and the intestinal fibroblast growth factor (FGF) 19 and 15. We investigated the role of activation of intestine-specific FXR in reducing hepatic levels of BAs and protecting the liver from cholestasis in mice., Methods: We generated transgenic mice that express a constitutively active FXR in the intestine. Using FXR gain- and loss-of-function models, we studied the roles of intestinal FXR in mice with intrahepatic and extrahepatic cholestasis., Results: Selective activation of intestinal FXR induced FGF15 and repressed hepatic Cyp7a1, reducing the pool size of BAs and changing the BA pool composition. Activation of intestinal FXR protected mice from obstructive extrahepatic cholestasis after bile duct ligation or administration of α-naphthylisothiocyanate. In Mdr2(-/-) mice, transgenic expression of activated FXR in the intestine protected against liver damage, whereas absence of FXR promoted progression of liver disease., Conclusions: Activation of FXR transcription in the intestine protects the liver from cholestasis in mice by inducing FGF15 expression and reducing the hepatic pool of BA; this approach might be developed to reverse cholestasis in patients., (Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
38. Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes.
- Author
-
Lo Sasso G, Celli N, Caboni M, Murzilli S, Salvatore L, Morgano A, Vacca M, Pagliani T, Parini P, and Moschetta A
- Subjects
- Animals, Cell Proliferation, Extracellular Matrix metabolism, Hepatectomy, Liver Regeneration, Liver X Receptors, Male, Matrix Metalloproteinase 9 genetics, Mice, Orphan Nuclear Receptors antagonists & inhibitors, Orphan Nuclear Receptors genetics, Triglycerides metabolism, Cholesterol metabolism, Gene Expression Profiling, Hepatocytes metabolism, Orphan Nuclear Receptors physiology
- Abstract
Cholesterol homeostasis is critical for cellular proliferation. Liver X receptor (LXR) alpha and beta are the nuclear receptors responsible for regulation of cholesterol metabolism. In physiological conditions, high intracellular cholesterol levels cause increased synthesis of oxysterols, which activate LXR, thus triggering a transcriptional response for cholesterol secretion and catabolism. Here we employed a mouse model of partial hepatectomy (PH) to dissect the molecular pathways connecting cholesterol homeostasis, cellular proliferation, and LXR. First, we show that hepatic cholesterol content increases after PH, whereas the entire LXR transcriptome is down-regulated. Although LXR messenger RNA (mRNA) levels are unmodified, LXR target genes are significantly down-regulated on day 1 after PH and restored to control levels on day 7, when the liver reaches normal size. The inactivation of LXR following PH is related to the reduced oxysterol availability by way of decreased synthesis, and increased sulfation and secretion. On the contrary, cholesterol synthesis is up-regulated, and extracellular matrix remodeling is enhanced. Second, we show that reactivation of LXR by way of a synthetic ligand determines a negative modulation of hepatocyte proliferation. This effect is sustained by the reactivation of hepatic cholesterol catabolic and secretory pathways, coupled with a significant reduction of cholesterol biosynthesis. Our data unveil a previously unrecognized and apparently paradoxical scenario of LXR modulation. During liver regeneration LXR activity is abated in spite of increasing intracellular cholesterol levels. Turning off LXR-transcriptional pathways is crucial to guaranteeing the requisite intracellular cholesterol levels of regenerating hepatocytes. In line with this hypothesis, pharmacological LXR reactivation during PH significantly reduces liver regeneration capacity.
- Published
- 2010
- Full Text
- View/download PDF
39. In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis.
- Author
-
Celli N, Dragani LK, Murzilli S, Pagliani T, and Poggi A
- Subjects
- Animals, Chlorogenic Acid blood, Cinnamates blood, Depsides blood, Drug Stability, Humans, Hydrolysis, Phenylethyl Alcohol administration & dosage, Phenylethyl Alcohol blood, Phenylethyl Alcohol pharmacokinetics, Rats, Rosmarinic Acid, Caffeic Acids administration & dosage, Caffeic Acids blood, Caffeic Acids pharmacokinetics, Phenylethyl Alcohol analogs & derivatives, Propolis chemistry
- Abstract
The in vitro biochemical stability of caffeic acid phenethyl ester in rat and human plasma was investigated and compared with the stability of other caffeic acid esters (chlorogenic acid and rosmarinic acid). The incubation of the compounds in rat plasma for up to 6 h showed that caffeic acid phenethyl ester, but not the other compounds, was hydrolyzed, whereas human plasma did not affect the stability of all the assayed compounds. The products in rat plasma were caffeic acid and an unknown compound, which was identified by mass spectrometry as caffeic acid ethyl ester, produced by transesterification in the presence of ethanol used as vehicle for standard compounds. Specific inhibitors of different plasma esterases allowed the identification of a carboxylesterase as the enzyme involved in the metabolism of caffeic acid phenethyl ester. The oral administration in rats of caffeic acid phenethyl ester in the presence of both ethanol and 2-(2-ethoxyethoxy)ethanol gave rise to a dramatic increase of caffeic acid, as well as low levels of caffeic acid phenethyl ester, caffeic acid ethyl ester, and caffeic acid 2-(2-ethoxyethoxy)ethyl ester, in urine collected within 24 h after treatment. These results suggest that caffeic acid phenethyl ester is hydrolyzed also in vivo to caffeic acid as the major metabolite and that its biological activities should be more properly assayed and compared with those of caffeic acid, its bioactive hydrolysis product. Moreover, alcohols should be carefully used in vivo as solvents for caffeic acid phenethyl ester, since they can give rise to new bioactive caffeic acid esters.
- Published
- 2007
- Full Text
- View/download PDF
40. Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
- Author
-
Tognon G, Bernasconi S, Celli N, Faircloth GT, Cuevas C, Jimeno J, Erba E, and D'Incalci M
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Cell Line, Tumor, Cyclosporine pharmacology, Dose-Response Relationship, Drug, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Enzyme Inhibitors pharmacology, Female, Genes, MDR, Humans, Peptides, Cyclic pharmacology, Antibiotics, Antineoplastic pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Phytogenic pharmacology, Depsipeptides pharmacology, Isoquinolines pharmacology, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology
- Abstract
Aplidin-resistant IGROV-1/APL cells were derived from the human ovarian cancer IGROV-1 cell line by exposing the cells to increasing concentration of Aplidin for eight months, starting from a concentration of 10 nM to a final concentration of 4 microM. IGROV-1/APL cell line possesses five fold relative resistance to Aplidin. IGROV-1/APL resistant cell line shows the typical MDR phenotype: (1) increased expression of membrane-associated P-glycoprotein, (2) cross-resistance to drugs like etoposide, doxorubicin, vinblastine, vincristine, taxol, colchicin and the novel anticancer drug Yondelis (ET-743). The Pgp inhibitor cyclosporin-A restored the sensitivity of IGROV-1/APL cells to Aplidin by increasing the drug intracellular concentration. The resistance to Aplidin was not due to the other proteins, such as LPR-1 and MRP-1, being expressed at the same level in resistant and parental cell line. The finding that cells over-expressing Pgp are resistant to Aplidin was confirmed in CEM/VLB 100 cells, that was found to be 5-fold resistant to Aplidin compared to the CEM parental cell line.
- Published
- 2005
- Full Text
- View/download PDF
41. Echo-enhanced ultrasonography: is it the future gold standard of imaging in acute pancreatitis?
- Author
-
Brocchi E, Piscaglia F, Bonora M, Celli N, Venturi A, Fantini L, Tomassetti P, Corinaldesi R, and Pezzilli R
- Subjects
- Acute Disease, Aged, 80 and over, Female, Humans, Magnetic Resonance Imaging, Pancreas pathology, Pancreatitis pathology, Severity of Illness Index, Tomography, X-Ray Computed, Ultrasonography methods, Pancreas diagnostic imaging, Pancreatitis diagnostic imaging
- Abstract
We report the imaging of a patient in whom the diagnosis of acute pancreatitis and the assessment of disease severity was carried out using echo-enhanced ultrasonography. Contrast-enhanced computed tomography confirmed the echo-enhanced ultrasonography picture. Echo-enhanced ultrasonography may become the imaging technique of choice in assessing the severity of acute pancreatitis since it is easy to perform, safe and lends itself to emergency situations. Most importantly, this technique should be also useful for following-up patients and it may be also an alternative to MRI in those patients in whom contrast-enhanced computed tomography cannot be carried out.
- Published
- 2005
42. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma.
- Author
-
Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, and Piscaglia F
- Subjects
- Aged, Body Weights and Measures, Carcinoma, Hepatocellular complications, Female, Humans, Liver diagnostic imaging, Liver Cirrhosis complications, Liver Neoplasms complications, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Tomography, Spiral Computed, Ultrasonography, Carcinoma, Hepatocellular diagnosis, Liver blood supply, Liver pathology, Liver Cirrhosis diagnosis, Liver Neoplasms diagnosis
- Abstract
In a prospective study, we examined the impact of arterial hypervascularity, as established by the European Association for the Study of the Liver (EASL) recommendations, as a criterion for characterizing small (1-3 cm) nodules in cirrhosis. A total of 72 nodules (1-2 cm, n = 41; 2.1-3 cm, n = 31) detected by ultrasonography in 59 patients with cirrhosis were included in the study. When coincidental arterial hypervascularity was detected at contrast perfusional ultrasonography and helical computed tomography, the lesion was considered to be hepatocellular carcinoma (HCC) according to EASL criteria. When one or both techniques showed negative results, ultrasound-guided biopsy was performed. In cases with negative results for malignancy or high-grade dysplasia, biopsy was repeated when an increase in size was detected at the 3-month follow-up examination. Coincidental hypervascularity was found in 44 of 72 nodules (61%; 44% of 1-2-cm nodules and 84% of 2-3-cm nodules). Fourteen nodules (19.4%) had negative results with both techniques (hypovascular nodules). Biopsy showed HCC in 5 hypovascular nodules and in 11 of 14 nodules with hypervascularity using only one technique. All nodules larger than 2 cm finally resulted to be HCC. Not satisfying the EASL imaging criteria for diagnosis were 38% of HCCs 1 to 2 cm (17% hypovascular) and 16% of those 2 to 3 cm (none hypovascular). In conclusion, the noninvasive EASL criteria for diagnosis of HCC are satisfied in only 61% of small nodules in cirrhosis; thus, biopsy frequently is required in this setting. Relying on imaging techniques in nodules of 1 to 2 cm would miss the diagnosis of HCC in up to 38% of cases. Any nodule larger than 2 cm should be regarded as highly suspicious for HCC.
- Published
- 2005
- Full Text
- View/download PDF
43. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography.
- Author
-
Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, and Bolondi L
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular blood supply, Contrast Media, Female, Humans, Liver Neoplasms blood supply, Magnetic Resonance Angiography, Male, Middle Aged, Prospective Studies, Tomography, Spiral Computed, Ultrasonography, Doppler, Color methods, Carcinoma, Hepatocellular diagnostic imaging, Liver Neoplasms diagnostic imaging
- Abstract
Background/aims: Diagnosis of hepatocellular carcinoma (HCC) relies strongly on the detection of hypervascularity in the arterial phase and, in this setting, spiral computed tomography (CT) is the most widely used method. This prospective study aimed to investigate the usefulness of low mechanical index harmonic ultrasound (US), using a second generation contrast-enhanced technique, in the assessment of vascular pattern of HCC shown to be hypervascular at spiral CT., Methods: A total of 79 cirrhotic patients with 103 nodules (mean+/-SD 28+/-13 mm) with arterial hypervascularity at spiral CT were studied. US examination was performed by perfusional sonography, using a new dedicated technology (CnTI-Esaote trade mark ), operating at low mechanical index, after injection of a second generation contrast agent (SonoVue trade mark -Bracco), allowing detection of tumoral flow during arterial phase., Results: Selective arterial enhancement on perfusional sonography was observed in 94 /103 nodules (91.3%), with a sensitivity of 66.6, 87.5, 91.7, and 97.3% in nodules =1 cm, >1=2 cm, >2=3 cm, and >3 cm respectively., Conclusions: Perfusional sonography shows good diagnostic agreement with spiral CT in hypervascular HCC and may be proposed for the immediate vascular characterization of nodules detected at US and used as second imaging technique to confirm hypervascularity in cirrhotic nodules.
- Published
- 2004
- Full Text
- View/download PDF
44. Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection.
- Author
-
Celli N, Mariani B, Di Carlo F, Zucchetti M, Lopez-Lazaro L, D'Incalci M, and Rotilio D
- Subjects
- Animals, Antineoplastic Agents blood, Antineoplastic Agents urine, Chromatography, Liquid methods, Humans, Peptides, Cyclic blood, Peptides, Cyclic urine, Antineoplastic Agents analysis, Depsipeptides, Peptides, Cyclic analysis, Spectrometry, Mass, Electrospray Ionization methods, Urochordata
- Abstract
A sensitive and highly specific liquid chromatographic method with electrospray ionisation tandem mass spectrometric detection (LC-ESI-MS/MS) is reported for the determination in human plasma, whole blood and urine of Aplidin (APL), a novel depsipeptide derived from the tunicate Aplidium albicans with a potent cytotoxic activity under investigation in clinical studies. Didemnin B was used as internal standard and, after protein precipitation with acetonitrile and liquid-liquid extraction with chloroform, APL was separated by liquid chromatography using a reversed-phase C18 column and a linear gradient of acetonitrile in water (both containing 0.5% formic acid). Detection was performed using a turboionspray source operated in positive ion mode and by multiple reaction monitoring (MRM; m/z 1111 --> 295 for APL and m/z 1113 --> 297 for didemnin B). The method was linear (r > or = 0.9933) over the range 1-250 ng/ml, with intra- and inter-batch precision and accuracy below 12.2% (except at LLOQ < or = 15.4%) for both plasma and urine. Recoveries were moderate, ranging from 54 to 70% in plasma and blood, and from 46 to 60% in urine, for both APL and didemnin B. The LOD was 0.25 ng/ml for both matrices. APL resulted stable in the different matrices at least for 6 h (both at room temperature and 37 degrees C), after freeze and thaw cycles and long term storage at -20 degrees C. The method allowed demonstrating that APL is in a dynamic equilibrium between plasma and blood cells. Moreover, the method was successfully applied to the pharmacokinetic study of Aplidin in cancer patients.
- Published
- 2004
- Full Text
- View/download PDF
45. Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy.
- Author
-
Piscaglia F, Gaiani S, Tamberi S, Celli N, Cecilioni L, Gramantieri L, and Bolondi L
- Subjects
- Acoustics, Aged, Carcinoma drug therapy, Disease Progression, Female, Hepatic Artery physiology, Humans, Liver blood supply, Liver Neoplasms drug therapy, Rectal Neoplasms drug therapy, Regional Blood Flow, Treatment Outcome, Ultrasonography methods, Carcinoma diagnostic imaging, Carcinoma secondary, Liver Neoplasms diagnostic imaging, Liver Neoplasms secondary, Rectal Neoplasms pathology
- Abstract
We used a new sonographic technique, real-time contrast-enhanced harmonic sonography at low acoustic energy, to evaluate liver perfusion and liver metastases from colorectal cancer in a 73-year-old woman after chemotherapy. After 6 weeks of chemotherapy, liver metastases that had been clearly visible on conventional sonography before chemotherapy were no longer detectable on conventional sonography but were still evident on contrast-enhanced sonography. At about 6 months after initiation of chemotherapy, the lesions were all visible again on conventional sonography and had become significantly larger, although some no longer showed contrast enhancement during the arterial phase. In this case, changes in arterial perfusion over time did not parallel the response of liver metastases to chemotherapy., (Copyright 2003 Wiley Periodicals, Inc.)
- Published
- 2003
- Full Text
- View/download PDF
46. Effect of Levovist on splanchnic hemodynamics in cirrhotic patients.
- Author
-
Gaiani S, Serra C, Piscaglia F, Celli N, Rasciti L, Miglioli M, and Bolondi L
- Subjects
- Aged, Female, Hemodynamics drug effects, Hepatic Artery diagnostic imaging, Hepatic Artery drug effects, Hepatic Artery physiopathology, Humans, Liver Cirrhosis diagnostic imaging, Male, Middle Aged, Splenic Artery diagnostic imaging, Splenic Artery drug effects, Splenic Artery physiopathology, Ultrasonography, Doppler, Vascular Resistance drug effects, Contrast Media pharmacology, Liver Cirrhosis physiopathology, Polysaccharides pharmacology, Splanchnic Circulation drug effects
- Abstract
This study was aimed to assess the effect of Levovist on Doppler parameters of splanchnic hemodynamics. A total of 12 patients with cirrhosis and 12 healthy subjects underwent Doppler ultrasound (US) examination of the portal vein and of the hepatic, splenic and superior mesenteric arteries before, 5 to 8 and 12 to 15 min after the start of an 8-min long IV infusion of 2.5 g of Levovist. Mean velocity and mean diameter were calculated for the portal vein. Resistance index was determined for the arteries. A significant increase of resistance index was observed in the hepatic (0.80 +/- 0.07 vs. 0.71 +/- 0.06; p < 0.01) and splenic arteries (0.72 +/- 0.06 vs. 0.64 +/- 0.06; p < 0.01) 5 to 8 min after contrast agent injection in patients with cirrhosis, but not in controls. Neither portal vein diameter nor portal flow mean velocity changed during the test in both controls and cirrhotic patients. This effect might be related to a selective trapping of microbubbles in the altered hepatic and splenic microvasculature in patients with cirrhosis rather than being artefactual. It might have implications on harmonic imaging US protocols designed to image the cirrhotic liver in the early arterial phase.
- Published
- 2003
- Full Text
- View/download PDF
47. Liquid chromatography-electrospray mass spectrometry study of cysteine-10 S-glutathiolation in recombinant glutathione S-transferase of Ochrobactrum anthropi.
- Author
-
Celli N, Motos-Gallardo A, Tamburro A, Favaloro B, and Rotilio D
- Subjects
- Amino Acid Sequence, Base Sequence, DNA, Bacterial, Molecular Sequence Data, Recombinant Proteins metabolism, Chromatography, Affinity methods, Cysteine metabolism, Glutathione Transferase metabolism, Ochrobactrum anthropi enzymology, Spectrometry, Mass, Electrospray Ionization methods
- Abstract
Glutathione S-transferase of Ochrobactrum anthropi (OaGST), a bacterium isolated from soils contaminated by xenobiotic pollutants, was recently purified, cloned and characterised in our laboratories. The recombinant OaGST (rOaGST), highly expressed in Escherichia coli, when purified by glutathione-affinity chromatography and then analysed by electrospray ionisation mass spectrometry (ESI-MS), has evidenced a disulphide bond with glutathione (S-glutathiolation), which was removable by reduction with 2-mercaptoethanol. Enzymatic digestion of rOaGST with endoproteinase Glu-C, followed by liquid chromatography (LC)-ESI-MS analyses of the peptide mixtures under both reducing and not reducing conditions, have shown that glutathione was covalently bound to the Cys10 residue of rOaGST. Furthermore, LC-ESI-MS analyses of overexpressed rOaGST in Escherichia coli crude extracts, with and without incubation with glutathione, have not shown any S-glutathiolation of the recombinant enzyme.
- Published
- 2003
- Full Text
- View/download PDF
48. Liquid chromatography-tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration.
- Author
-
Del Boccio P, Di Deo A, De Curtis A, Celli N, Iacoviello L, and Rotilio D
- Subjects
- Administration, Oral, Animals, Calibration, Iridoid Glucosides, Iridoids, Phenylethyl Alcohol blood, Phenylethyl Alcohol urine, Pyrans administration & dosage, Pyrans blood, Pyrans urine, Rats, Sensitivity and Specificity, Phenylethyl Alcohol analogs & derivatives, Phenylethyl Alcohol analysis, Pyrans analysis
- Abstract
We describe a liquid chromatography-electrospray ionisation tandem mass spectrometry method for the qualitative and quantitative determination of the secoiridoid oleuropein and its bioactive metabolite hydroxytyrosol in rat plasma and urine. Samples were prepared by liquid-liquid extraction using ethyl acetate with a recovery for both compounds of about 100% in plasma and about 60% in urine. The chromatographic separation was performed with a RP-ODS column using a water-acetonitrile linear gradient. The calibration curve was linear for both biophenols over the range 2.5-1000 ng/ml (LOD 1.25 ng/ml) for plasma and 5-1000 ng/ml (LOD 2.5 ng/ml) for urine. Plasma concentrations of oleuropein and hydroxytyrosol were measured after oral administration of a single dose (100 mg/kg) of oleuropein. Analysis of treated rat plasma showed the presence of unmodified oleuropein, reaching a peak value of 200 ng/ml within 2 h, with a small amount of hydroxytyrosol, whereas in urine, both compounds were mainly found as glucuronides.
- Published
- 2003
- Full Text
- View/download PDF
49. Amino acid sequence of the major form of toad liver glutathione transferase.
- Author
-
Bucciarelli T, Sacchetta P, Amicarelli F, Petruzzelli R, Melino S, Rotilio D, Celli N, and Di Ilio C
- Subjects
- Amino Acid Sequence, Animals, Bufo bufo, Kinetics, Molecular Sequence Data, Sequence Homology, Amino Acid, Glutathione Transferase chemistry, Liver enzymology
- Abstract
To investigate structural relationship between amphibian and mammalian GSTs the complete amino acid sequence of the major form of glutathione transferase present in toad liver (Bufo bufo) was determined. The enzyme subunit is composed of 210 amino acid residues corresponding to a molecular mass of 24,178 Da. In comparison with the primary structure of amphibian bbGSTP1-1, toad liver GST showed 54% sequence identity. On the other hand, toad liver GST showed about 45-55% sequence identity when compared with other pi class GST and less then 25% identity with GST of other classes. Amino acid residues involved in the H site and in the key and lock structure of the toad enzyme are significantly different from those of bbGSTP1-1 and other mammalian pi class GST. On the basis of its structural and immunological properties the toad liver GST, indicated as bbGSTP2-2, could represent the prototype of a subset of the pi family., (Copyright 2002 Elsevier Science Ltd.)
- Published
- 2002
- Full Text
- View/download PDF
50. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma.
- Author
-
Bolondi L, Gaiani S, Celli N, and Piscaglia F
- Subjects
- Humans, Carcinoma, Hepatocellular surgery, Catheter Ablation adverse effects, Liver Neoplasms surgery, Neoplasm Seeding
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.